To include your compound in the COVID-19 Resource Center, submit it here.

MetMAb: Final Phase II data

Final data from the double-blind, international Phase II OAM4558g trial in 137 patients showed that 15 mg/kg IV MetMAb every 3 weeks plus Tarceva erlotinib missed the co-primary endpoint of significantly

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE